Form DEFA14A Adverum Biotechnologies,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall St slides as hot CPI data fuels rate-hike bets; chips, banks weigh
- Oil prices steady after gains on Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
RBC Capital Downgrades Adverum Biotechnologies (ADVM) to Sector Perform
April 29, 2021 6:18 AM EDTRBC Capital analyst Luca Issi downgraded Adverum Biotechnologies (NASDAQ: ADVM) from Outperform to Sector Perform with a price target of $6.00 (from $30.00).
The analyst comments "ADVM announced a serious adverse event of hypotony (decreased intraocular pressure), panuveitis and loss of vision in a DME... More



